Feb. 24 at 10:37 PM
$BCDA March 2nd expect a PR for Phase 3 Readout.
Phase III CardiAMP cell therapy targeting a
$17B+ heart‑failure market, backed by FDA Breakthrough Designation.
Late‑breaking clinical data accepted for presentation at THT 2026 — rare spotlight for a microcap.
Helix delivery system with 4,000+ cardiac injections heading toward FDA De Novo submission in Q3 ‘25.
Analysts projecting massive upside, with targets ranging from
$4 →
$25 and Strong Buy ratings.
Trading at microcap levels (~
$12M) near 52‑week lows, making BCDA a high‑volatility catalyst rocket waiting for ignition.
